Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind trial of vamorolone versus prednisone and placebo in ambulatory boys with Duchenne muscular dystrophy
MOH_2018-08-23_003612Phase 2Not yet recruiting
- Sponsor
- ReveraGen BioPharma
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vamorolone in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by ReveraGen BioPharma. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2018-08-23_003612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-23_003612.